CDK4/6 Inhibitors for Breast Cancer — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following topics:
- Introduction (00:00)
- Advent of CDK4/6 Inhibitors in HR-Positive Breast Cancer (BC) (1:24)
- Risk Assessment for Patients with HR-Positive, HER2-Negative Localized BC (2:52)
- Adjuvant CDK4/6 Inhibitor Therapy (17:14)
- Practical Considerations with CDK4/6 Inhibitors (29:57)
- Monitoring and Management of Cytopenias (42:02)
- CDK4/6 Inhibitors in HR-Positive Metastatic BC (49:32)
- Management of Gastrointestinal Adverse Events (1:03:47)
- CDK4/6 Inhibitors in Unique Populations (1:10:41)
- Rarer CDK4/6 Inhibitor-Associated Toxicities (1:19:48)
